Drug intelligence / Profile preview

XXX-Lean

Development stage
Unknown
Lead developer
UK Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

XXX-Lean is a multi-ingredient dietary supplement marketed for weight loss and thermogenesis. It is primarily known for being the subject of regulatory seizures by Health Canada due to its inclusion of unauthorized and potentially hazardous substances. The formulation typically contains MaHuang extract (standardized for ephedrine), Guarana extract (standardized for caffeine), and L-carnitine. Ephedrine acts as a sympathomimetic agent that stimulates the central nervous system and increases metabolic rate, while caffeine provides additional stimulation and enhances the thermogenic effect. This combination, often referred to as an 'ECA stack' (though carnitine replaces aspirin here), is intended to promote fat loss but is associated with significant cardiovascular risks, including increased heart rate and blood pressure. The product has been manufactured by entities such as UK Pharma and EU Pharma, often through contract manufacturers like Professional Botanicals Inc.

Brand names
XXX-Lean
Other names
EU Pharma XXX-LeanUK Pharma XXX-Lean
02

Targets

MOR (Mu opioid receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on XXX-Lean.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on XXX-Lean.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call